Simultaneously target of normal and stem cells-like gastric cancer cells via cisplatin and anti-CD133 CAR-T combination therapy

Han, Yang; Sun, Bo; Cai, Hong; Yao, Xuan

doi:10.1007/s00262-021-02891-x

Cited by 32 publications

(18 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Indeed, CAR-T cell therapy still faces many problems, and finding new targets is the key to improving the therapeutic efficacy. Researchers substantiated the effectiveness of CAR-T cells targeting PSCA, FRα, PD-L1, c-MET, CD133, CDH17, ICAM-1, and urokinase plasminogen activator surface receptor (uPAR) in GC models in the last 2 years [255,[269][270][271][272][273][274][275].…”

Section: Gastric Cancer (Gc)mentioning

confidence: 99%

Tumor buster - where will the CAR-T cell therapy ‘missile’ go?

Zhang

Cao

et al. 2022

Mol Cancer

View full text Add to dashboard Cite

Chimeric antigen receptor (CAR) T cell (CAR-T cell) therapy based on gene editing technology represents a significant breakthrough in personalized immunotherapy for human cancer. This strategy uses genetic modification to enable T cells to target tumor-specific antigens, attack specific cancer cells, and bypass tumor cell apoptosis avoidance mechanisms to some extent. This method has been extensively used to treat hematologic diseases, but the therapeutic effect in solid tumors is not ideal. Tumor antigen escape, treatment-related toxicity, and the immunosuppressive tumor microenvironment (TME) limit their use of it. Target selection is the most critical aspect in determining the prognosis of patients receiving this treatment. This review provides a comprehensive summary of all therapeutic targets used in the clinic or shown promising potential. We summarize CAR-T cell therapies’ clinical trials, applications, research frontiers, and limitations in treating different cancers. We also explore coping strategies when encountering sub-optimal tumor-associated antigens (TAA) or TAA loss. Moreover, the importance of CAR-T cell therapy in cancer immunotherapy is emphasized.

show abstract

Section: Gastric Cancer (Gc)mentioning

confidence: 99%

Tumor buster - where will the CAR-T cell therapy ‘missile’ go?

Zhang

Cao

et al. 2022

Mol Cancer

View full text Add to dashboard Cite

show abstract

“…In the strategy of CAR-T treatment of GC, multiple targets have been proved to be effective in the treatment of xenograft mouse GC model, such as mesothelin (MSLN), prostate stem cell antigen (PSCA), B7 homology 3 (B7H3) protein, and NK group 2 member D (NKG2D) (102)(103)(104)(105). In addition, CAR-T targeting carcinoembryonic antigen (CEA), HER2, CLDN18.2, FOLR1, c-Met, CD133, and CDH17 had a significant anti-tumor effect in the corresponding target-positive GC mouse model and the tumor appeared partially or even complete regression (106)(107)(108)(109)(110)(111)(112). CAR-T cells targeting ICAM-1 can effectively eliminate tumors developing in the lungs in animal models of GC (113).…”

Section: Car-tmentioning

confidence: 99%

Therapeutic strategies for gastric cancer targeting immune cells: Future directions

et al. 2022

View full text Add to dashboard Cite

Gastric cancer (GC) is a malignancy with a high incidence and mortality, and the emergence of immunotherapy has brought survival benefits to GC patients. Compared with traditional therapy, immunotherapy has the advantages of durable response, long-term survival benefits, and lower toxicity. Therefore, targeted immune cells are the most promising therapeutic strategy in the field of oncology. In this review, we introduce the role and significance of each immune cell in the tumor microenvironment of GC and summarize the current landscape of immunotherapy in GC, which includes immune checkpoint inhibitors, adoptive cell therapy (ACT), dendritic cell (DC) vaccines, reduction of M2 tumor-associated macrophages (M2 TAMs), N2 tumor-associated neutrophils (N2 TANs), myeloid-derived suppressor cells (MDSCs), effector regulatory T cells (eTregs), and regulatory B cells (Bregs) in the tumor microenvironment and reprogram TAMs and TANs into tumor killer cells. The most widely used immunotherapy strategies are the immune checkpoint inhibitor programmed cell death 1/programmed death-ligand 1 (PD-1/PD-L1) antibody, cytotoxic T lymphocyte–associated protein 4 (CTLA-4) antibody, and chimeric antigen receptor T (CAR-T) in ACT, and these therapeutic strategies have significant anti-tumor efficacy in solid tumors and hematological tumors. Targeting other immune cells provides a new direction for the immunotherapy of GC despite the relatively weak clinical data, which have been confirmed to restore or enhance anti-tumor immune function in preclinical studies and some treatment strategies have entered the clinical trial stage, and it is expected that more and more effective immune cell–based therapeutic methods will be developed and applied.

show abstract

“…J Jiang et al found that trastuzumab inhibits the stemness of GC cells by inhibiting ERBB2 signaling [ 149 ]. The stemness inhibitory effect of cisplatin in GC was discovered by Yang Han et al [ 150 ].…”

Section: Drugs For Gc Treatment By Targeting Its Stemnessmentioning

confidence: 99%

Targeting Gastric Cancer Stem Cells to Enhance Treatment Response

Rao

Zhang

Luo

et al. 2022

Cells

View full text Add to dashboard Cite

Gastric cancer (GC) was the fourth deadliest cancer in the world in 2020, and about 770,000 people died from GC that year. The death of patients with GC is mainly caused by the metastasis, recurrence, and chemotherapy resistance of GC cells. The cancer stem cell theory defines cancer stem cells (CSCs) as a key factor in the metastasis, recurrence, and chemotherapy resistance of cancer. It considers targeting gastric cancer stem cells (GCSCs) to be an effective method for the treatment of GC. For GCSCs, genes or noncoding RNAs are important regulatory factors. Many experimental studies have found that some drugs can target the stemness of gastric cancer by regulating these genes or noncoding RNAs, which may bring new directions for the clinical treatment of gastric cancer. Therefore, this review mainly discusses related genes or noncoding RNAs in GCSCs and drugs that target its stemness, thereby providing some information for the treatment of GC.

show abstract

Simultaneously target of normal and stem cells-like gastric cancer cells via cisplatin and anti-CD133 CAR-T combination therapy

Cited by 32 publications

References 25 publications

Tumor buster - where will the CAR-T cell therapy ‘missile’ go?

Tumor buster - where will the CAR-T cell therapy ‘missile’ go?

Therapeutic strategies for gastric cancer targeting immune cells: Future directions

Targeting Gastric Cancer Stem Cells to Enhance Treatment Response

Contact Info

Product

Resources

About